Home › Funds › Azimuth Capital Investment Management LLC › NBIX

Azimuth Capital Investment Management LLC position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Azimuth Capital Investment Management LLC reported holding 136,510 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$19.4M, representing 0.67% of its reported portfolio and ranking #44 among its reported holdings. Azimuth Capital Investment Management LLC has disclosed NBIX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)136.51K sh
Reported value held$19.36M
Portfolio Weight0.67%
First reportedQ1 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Azimuth Capital Investment Management LLC's NBIX position evolved

Azimuth Capital Investment Management LLC first disclosed a stake in NBIX in Q1 2024 at 64,539 shares (US$8.9M). The position peaked in Q3 2026 at 136,510 shares, worth US$19.4M. Across 11 filings, Azimuth Capital Investment Management LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 136,510 shares valued at US$19.4M — an increase of 24,044 shares quarter over quarter.. Notable position changes include a 74% increase in Q3 2024 (shares rose 18% over the following quarter), a 31% trim in Q1 2025 (shares rose 14% over the following quarter), a 73% increase in Q4 2025 (shares fell 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 64.54K $8.90M New
Q2 2024 66.41K $9.14M Add
Q3 2024 115.38K $13.29M Add
Q4 2024 115.31K $15.74M Hold
Q1 2025 79.32K $8.77M Reduce
Q2 2025 72.00K $9.05M Reduce
Q3 2025 70.68K $9.92M Reduce
Q4 2025 122.28K $17.34M Add
Q1 2026 121.70K $16.03M Hold
Q2 2026 112.47K $18.95M Reduce
Q3 2026 136.51K $19.36M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 30 other funds we track also report a position in NBIX — the largest reported positions include Two Sigma Investments (US$349.9M), Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Azimuth Capital Investment Management LLC held NBIX?

Azimuth Capital Investment Management LLC has disclosed NBIX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Azimuth Capital Investment Management LLC's current position in NBIX?

As of Q3 2026, Azimuth Capital Investment Management LLC holds 136.51K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $19.36M, representing 0.67% of its reported portfolio and ranking #44.

Has Azimuth Capital Investment Management LLC been buying or selling NBIX?

In the latest 13F filing (Q3 2026), Azimuth Capital Investment Management LLC increased its position in NBIX. The position peaked in Q3 2026 at 136.51K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Two Sigma Investments, Renaissance Technologies, Vestal Point Capital, LP, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.